Оценка эффективности реперфузионной терапии и прогноз у больных инфарктом миокарда по данным радионуклидных методов исследования

Список литературы

1. Wood М. A., Spores J., Notske R., et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N. Engl. J. Med. 1980- 303: 897−902.
2. Ganz W., Buchbinder N., Marcus H., et al. Intracoronary thrombolysis in evolving myocardial infarction. Am. Heart J. 1981- 101:4−13.
3. Reimer K., Jennings R. Factors involved in salvaging ischemic myocardium: effect of reperfusion of arterial blood. Circulation 1983- 68 suppl I: 125−36.
4. Reimer K., Jennings R. The «wavefront phenomenon» of myocardial ischemic cell death. Transmural progression of necrosis within the framework of ischemic bed size /myocardium at risk/ and collateral flow. Lab. Invest. 1979- 40: 633−44.
5. Reimer K., Lowe J., Rasmussen M., et al. The «wavefront phenomenon» of ischemic cell death: myocardial infarction size versus duration of coronary occlusion in dogs. Circulation 1977- 56: 786−94.
6. Чазов E. И., Матвеева Jl. С., Мазаев А. В. с соавт. Внутрикоронарное введение фибринолизина при остром инфаркте миокарда. Терапевтический архив 1976- 4: 8−19.
7. Gruppo Italiano per lo Studio della Streptohinasi nell’Infarto Miocardico. Long-term effects of intravenous thrombolysisin acute myocardial infarction: final report of the GISSI Study. Lancet 1988- 2: 871−4.
8. The ISAM Study Group. A prospective trial of Intravenous Streptokinase in Acute Myocardial Infarction (ISAM): mortality, morbidity and infarct size at 21 days. N. Engl. J. Med. 1986- 314: 1465−71.
9. ISIS 2 Colloborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS 2. Lancet 1988- 2: 349−60.
10. The AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet 1988- 1: 545−9.
11. Vorcheimer D. A. GUSTO I medication errors abstract. Circulation 1997−96 (suppl I):535.
12. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N. Engll. J. Med. 1997−337:1118−1123.
13. Topol E. J. Toward a new frontier in myocardial reperfusion therapy. Emerging platelet preeminence. Circulation 1998−97:211−218.
14. Gassier J. P., Topol E. J. Reperfusion revisited: beyond TIMI 3 flow. Clin Cardiol. 1999- 22 (suppl IV): IV 20-IV 29.
15. Kleiman N. S., Ohman E. M., CaliffR. M., Topol E. J. et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after trombolytic therapy: results of the Trombolysis and Angioplasty in
16. Myocardial Infarction (TAMI) 8 pilot study. J. Allergy. Clin. Immunol. 1993- 22: 381−89.
17. Stone G. W.,, Rutherford B. D., McConahay D. R., et al. Direct coronary angioplasty in acute myocardial infarction: outcome in patients with single vessel disease. J. Am. Coll. Cardiol. 1990- 15: 534−43.
18. Neuman F. J., Kosa I., Dickfeld T., et al. Recovery of myocardial perfusion in acute myocardial infarction after successful balloon angioplasty and stent placement in the infarct-related coronary artery. J. Am. Coll. Cardiol. 1997- 30: 1270−76.
19. Behrenbeck T., Patricia A. P., Kenneth C. H., et al. Primary angioplasty in myocardial infarction: assessment of Improved myocardial perfusion with Technetium-99m Isonitrile. J. Am. Coll. Cardiol. 1991- 17: 365−72.
20. Hartzler G. O., Rutherford B. D., McConahay D. R., et al. Percutaneous transluminal coronary angioplasty with and without thrombolytic therapy for treatment acute myocardial infarction. Am. Heart J. 1983- 106: 965−73.
21. Hartzler G. 0.,, Rutherford B. D., McConahay D. R., et al. Percutaneous transluminal coronary angioplasty: application for acute myocardial infarction. J. Am. Coll. Cardiol. 1984- 53: 17C-21C.
22. Kimura T., Nosaka H., Ueno K., Nobuyoshi M. Role of coronary angioplasty in acute myocardial infarction. Am. Heart J. 1984- 107: 820−2.
23. Rothbaum D. A., Linnemeir T. J., Landin R. J., et al. Emergency percutaneous transluminal coronary angioplasty in acute myocardial infarction: a 3 year experience. J. Am. Coll. Cardiol. 1987- 10: 264−72.
24. Marco J., Caster L., Szatmary L. J., Fajadet J. Emergency percutaneous transluminal coronary angioplasty without thrombolysis as initial therapy in acute myocardial infarction. Int. J. Cardiol. 1987- 15: 55−63.
25. O’Keefe J. H., Rutherford B. D., McConahay D. R., et al. Early and late results of coronary angioplasty without antecedent thrombolytis therapy for acute myocardial infarction. J. Am. Coll. Cardiol. 1989- 64: 1221−30.
26. Topol E. J. Coronary angioplasty for acute myocardial infarction. Ann. Intern. Med. 1988- 109: 970−80.
27. Ellis S. G., O’Neill W. W., Bates E. R., et al. Coronary angioplasty as primary therapy for acute myocardial infarction 6 to 48 hours after sympton onset: repot of an initial experience. J. Am. Coll. Cardiol. 1989- 13: 1122−6.
28. Topol E. J. RAPPORT: outcomes in patients with acute myocardial infarction with abciximab and primary PTCA. Presented at the XIX Congress of the European Society of Cardiology, Stockholm, Sweden, August 24−28,1997.
29. Serruys P.W., de Jaegere P., Kiemeneij F. et al for the BENESTENT Study Group. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N. Engl. J. Med. 1994- 331:489−95.
30. Eleckhout E., Kern M. J. The coronary no-reflow phenomenon: a review of mechanism and therapies. Eur. Heart J. 2001- 22: 729−39.
31. Ven de Werf F. Discrepancies between the effect of coronary reperfusion on survival and left ventricular function. Lancet 1989- 1: 1367−69.
32. Gibson C. M., Cannon C. P., Daley W. L. et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 1996- 93: 879−88.
33. Krug A., de Rochemont W. M., Korb G. Blood supply to the myocardium after temporary coronary occlusion. Circ. Res. 1966- 19: 57−62.
34. Kloner R. A., Ganote C. E., Jennings R. B. The «no-reflow» phenomenon after temporary coronary occlusion in the dog. J. Clin. Invest. 1974- 54: 1496−508.
35. Schofer J., Montz R., Mathey D. G. Scintigraphic evidence of the «no-reflow» phenomenon in human beings after coronary thrombolysis. J. Am. Coll. Cardiol. 1985−5:593−98.
36. Ito H., Tomooka T., Sakai N., et al. Lack of myocardial perfusion immediately after successful thrjmbolysis. Circulation 1992- 85: 1699−1705.
37. Ito H., Maruyama A., Iwakura K., et al. Clinical implications of the «no-reflow» phenomenon: a predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation 1996- 93: 223−228.
38. Morishima J., Sone T., Mokuno S. et al. Clinical significance of no-reflow phenomenon observed on angiography after successful treatment of acutemyocardial infarction with percutaneous transluminal coronary angioplasty. Am. Heart J. 1995- 130: 239−243.
39. Boli R., Triana J. E., Jeround M. O. Prolonged impairment of coronary vasodilation after reversible ischemia. Evidence for microvascular stunning. Circulat. Res. 1990: 67: 332−43.
40. Kloner R. A. Does reperfusion exist in human? J. Am. Coll. Cardiol. 1993- 21:3775−81.
41. Ambrosio G., Weisman H. F., Mannisi J. A., Becker L. C. Progressive impairment of regional myocardial perfusion after initial restoration of postischemic blood flow. Circulation 1989- 80: 1846−61.
42. Kloner R. A., Rude R. E., Carlson N., et al. Ultrastructural evidence of microvascular damage and myocardial cell injury after coronary occlusion: which comes fist? Circulation 1980- 62. 945−52.
43. Seydoux C., Goy J. J., Davies G. Platelet and neutrophyl imagina techniques in the investigation of the response to thrombolytic therapy and the no-reflow phenomenon. Am. Heart J. 1993- 125: 1142−47.
44. Bolli R. Mechanism of myocardial «stunning». Circulation 1990- 82: 72 338.
45. Braunwald E., Kloner R. A., et al. The stunned myocardium: pro- longed, postichemic ventricular dysfynction. Circulation 1982- 66: 1146−49.
46. Downing S. E. Wall tension and myocardial dysfynction after ischemic and reperfusion. Am. J. Physiol. 1993- 264: 386−93.
47. Ferrari R., La Canna G., Glubbini R., et al. Hibernating myocardium in patients with coronary artery disease: identification and clinical importance. Cardiovasc. Drugs Ther. 1992- 6: 287−93.
48. Соколова Р. И., Жданов В. С. Патоморфология «оглушенного» миокарда при операциях аортокоронарного шунтирования. Кардиология 1999- 10: 23−6.
49. Birnbaum J., Kloner R. A. Therapy for myocardial stunning. Ibid 1996- 1035.
50. Pfeffer M. A., Braunwald E. Ventricular remodeling after myocardial infarction: experimental observation and clinical implications. Circulation 1990- 81: 1161−72.
51. Sabbah H. N., Goldstein S. Ventricular remodelling: consequences and therapy. Eur. Heart J. 1993- 14: C: 24−29.
52. Eng C., Zhao M., Factor S. M., Sonnenblick E. H. Post-ischaemic cardiac dilatation and remodeling: reperfusion injury of the interstitium. Eur. Heart J. 1993- 14: A: 27−32.
53. Hutchins G. M., Bulkley В. H. Infarct expansion versus extension: two diffrenet complication of acute myocardial infarction. J. Am. Coll. Cardiol. 1978- 41: 1127−32.
54. Welsman H. R., Bush D. В., Mannisti J.A., et al. Cellular mechanisms of myocardial infarction expansion. Circulation 1988- 78: 184−201.
55. Irimpen A. M., Tenaglia A. N., Scin D. J., Buda A. J. Lack of ventricular remodeling in non-Q-wave myocardial infarction. Am. Heart J. 1996- 131: 466−71.
56. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993- 342: 821−28.
57. Picard M. H., Wilkins G. T., Gollam L. D. et al. Immediate regional endocardial surface expansion following coronary occlusion in the canine left ventricle: disproportionate effects of anterior versus inferior ischemia. Am. Heart J. 1991- 121:753−62.
58. Jeremy R. W., Allman K. C., Bautovitch G., et al. Patterns of left ventricular dilatation during the six months after myocardial infarction. J. Am. Coll. Cardiol. 1989- 33: 304−10.
59. Anderson J. L., Marshall H. W., Bray B. E., et al. A randomized trial of streptokinase in the treatment of acute myocardial infarction. N. Engl. J. Med. 1983- 308: 1312−18.
60. Blanke H., Scherff F., Karsch K.R., et al. Electrocardiographic changes after streptokinase-induced recanalization in patients with acute left anterior descending artery obstruction. Circulation 1983- 68: 406−12.
61. Von Essen R., Schmidt W., Vebis R., et al. Myocardial infarction and thrombolysis: electrocardiografic short and long term results using precordial mapping. Br. Heart J. 1985- 54: 6−10.
62. Bren G. B., Wasserman A. G., Ross A. M. The electrocardiogram in patients undergoing thrombolysis for myocardial infarction. Circulation 1987- 76 (suppl II): 11−18−24.
63. Galli M., Marcassa C., Bolli R., et al. Spontaneous delayed recovery of perfusion and contraction after the first 5 weeks after anterior infarction. Circulation 1994- 90: 1386−97.
64. Pfisterer M., Zuberg M., Wenzel R., Burkart F. Prolonged myocardial stunning after thrombolysis: can left ventricular function be assessed definitely at hospital discharge? Eur. Heart J. 1991- 12: 214−217.
65. Rahimtola S. The hibernating myocardium. Am. Heart J. 1989- 117: 211 -221.
66. Kim R. J., Lima A. C., Chen E-L, et al. Fast 23Na Magnetic resonance imaging of acute reperfused myocardial infarction. Am. Heart Association 1997- 95: 1877−85.
67. Niemeyer M. G., Van der Wall E. E., de Roos A., et al. Assessement of acute myocardial infarction by nuclear imaging techniques. Angiology 1992- 9: 720−733.
68. Bouchard A., Reeves R. S., Cranney G., et al. Assessement of myocardial infarct size by means of T2-weighted 1H nuclear magnetic resonance imaging. Am. Heart J. 1989- 117: 281−9.
69. De Roos A., Matheijssen N. A. A., Doornbos J., et al. Assessement of myocardial infarct size after reperfusion therapy using gadolinium-DTPA enhanced magnetic resonance imaging. Radiology 1990- 176: 517−21.
70. Van Rossum A. C., Visser F. C., Van Eenige M. J., et al. Value of gadolinium-DTPA dynamics in magnetic resonance imaging of acutemyocardial infarction with occluded and reperfused coronary arteries after thrombolysis. Am. J. Cardiol. 1990- 65: 845−51.
71. Camici P. G. Positron emission tomography and myocardial imaging. Heart 2000- 83: 475−80.
72. Jeremy R. W., Links J. M., Becker L. C. Progressive failure of coronary flow during reperfusion of myocardial infarction: documentation of the no-reflow phenomenon with positron emission tomography. J. Am. Coll. Cardiol. 1990- 16: 695−704.
73. Rogers W. J., Bourge R. C., Papapietro S. E., et al. Variables predictive of good functional outcome following thrombolytic therapy in the thrombolysis in myocardial infarction (TIMI) phase II study. Am. J. Cardiol. 1989- 63: 503−12.
74. Taylor Y. I., Humphries I. O., Mellits E. D., et al. Predictors of clinical course, coronary anatomy and left ventricular function after recovery from acute myocardial infarction. Circulation 1980- 62: 960−70.
75. The Multicenter Post-infarction Research Group. Risk stratification and survival after myocardial infarction. N. Engl. J. Med. 1983- 309: 331−36.
76. Rogers W. J., Smith L. R., Oberman A., et al. Surgical versus nonsurgical management of patients after myocardial infarction. Circulation 1980, 62 (suppl I): I-67-I-74.
77. Schulman S. P., Achuff S. C., Giffith L. S. C., et al. Prognostic cardiac catheterization variables in survivors of acute myocardial infarction: a five years prospective study. J. Am. Coll. Cardiol. 1988- 11: 1164−72.
78. Perez-Gonsalez J. F., Botvinick E. H., Dunn R. Et al. Late prognostic value of scintigraphic parameters of acute scintigraphic measurement of myocardial infarction size. Circulation 1982- 66: 960−71.
79. Miller T. D., Hodge D. O., Sutton J. M., et al. Technetium-99m sestamibi infarct size predicts mortality. Am. J. Cardiol. 1998−81: 1491−93.
80. Miller T. D., Christian T. F., Hodge D. O., et al. Infarct size after acute myocardial infarction measured quantitative tomographic technetium-99m sestamibi imaging subsequent mortality. Circulation 1995- 92: 334−41.
81. Burns R. J., Gibbons R. J., Roberts R. S., et al. LV function and infarct size predict six-month mortality post myocardial infarction treated by thrombolysis. Circulation 1996- 94 (suppl I): 1−655.
82. Feiring A. J., Johnson M. R., Kioschos J. M., et al. The importance of the myocardial area at risk in the evaluation of the outcome of acute myocardial infarction in patients. Circulation 1987−75: 980−987.
83. White H. D., Norris R. M., Brown M. A., et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987- 76- 44−51.
84. Самойленко Л. E., Ширяев А. А., Скридлевская E. К., Акчурин P. C. Применение томосцинтиграфии миокарда для определения жизнеспособности миокарда у больных ишемической болезнью. Вестник рентгенологии и радиологии. 1996 г. № 6. Стр. 34−35.
85. Самойленко JT. Е. Перфузионная сцинтиграфия миокарда в клинической кардиологии. Диссертация доктора мед. наук. Москва. 1998 г.
86. Сергиенко В. Б. Однофотонная эмиссионная компьютерная томография. Опыт клинического применения. Диссертация доктора мед. наук. Москва 1984 г.
87. Сергиенко В. Б, Щербанкин JI. Д., Борисенко О. П. Однофотонная эмиссионная компьютерная томография с 201Т1 в диагностике ишемической болезни сердца. Терапевтический архив 1985. № 4. Стр. 95−99.
88. Сергиенко В. Б., Самойленко J1.E., Ходарева Е. Н., Паша С. П. Перфузионная сцинтиграфия миокарда: взгляд через 25 лет. Практикующий врач 1999, 15: 20−24.
89. Wahba F. М., Bavelaar-Croon D. L., Baur Н. В. et al. Detection of residual wall motion after sustained myocardial infarction by gated 99m-tetrofosmin SPECT: a comparison with echocardioraphy. Nucl. Med. Commun. 2001- 22: 175−82.
90. Паша С. П., Михеев В. Э., Сергиенко В. Б. Синхронизированная томосцинтиграфия миокарда с 99мТс-МИБИ в оценке общей сократительной функции левого желудочка. Вестник рентгенологии и радиологии 2000- 1: 21−25.
91. Achtert A. D., King М. A., Dahlberg S. Т. et al. An investigation of the estimation of ejection fractions and cardiac volumes by a quantitative gated SPECT software package in simulated gated SPECT images. J. Nucl. Cardiol. 1998- 5: 144−52.
92. Duska F., Vizda J., Kubicek J., et. al. The sinsitivity of scintigraphic myocardial imaging by the use of 99m-Tc- labeled pyraphosphate in the diagnosis of cardiomyopathy of various etiology. Eur. J. Nucl. Med. 1979, V 4, p 87−90.
93. Двоскина И. С. Диагностическое значение сцинтиграфии миокарда с 99 м Тс-пирофосфатом. Диссертация кандидата мед. наук. Москва 1980.
94. Eckelman W. С., Reba R. S., Kubota Н., et. al. 99m Тс pyraphosphate for bone imaging. J. Nucl. Med. 1976, V 15, p 274−83.
95. Khaw B. A., Gold H. K., Yasuda T. et al. Scintigraphic quantification of myocardial necrosis in patients after intravenous injection of myosin-specific antibody. Circulation 1986- 74: 501−8.
96. Wackers F. J. Т., Busseman S. E., Samson G., et al. Value and limitations of thallium-201 scintigraphy in the acute phase of myocardial infarction. N. Engl. J. Med. 1976- 295: 1−5.
97. Tamaki S., Kambara H., Suzuki Y., et al. Improved detection of myocardial infarction by emission computed tomography with thallium-201. Relation to infarct size. Br. Heart J. 1984- 52: 621−27.
98. Ritchie J.L., Williams D. L., Harp G., et al. Transaxial quantitl tomography with thallium-201 for detecting remote myocardial infarction. Comparison with planar imaging. Am. J. Cardol. 1982- 50: 1236−41.
99. Kichner P. Infarct size with thallium-201 scintigraphy. Am. J. Cardol. 1990- 4: 46−58.
100. DiCola V. C., Downing S. E., Donabedian R. K, et al. Pathophysiological correlates of thallium-201 myocardial uptake in experimental infarction. Cardiovasc. Res. 1977- 11: 141−46.
101. Okada R. D., Lim Y. L., Kaul S., et al. Quantitation of myocardial infarct size from thallium-201 images: Validation of a new approach in an experimental model. J. Am. Coll. Cardiol. 1984- 3: 948−55.
102. Nelson A. D., Khullar S., Budd G. S., et al. ation of thallium-201 scintigrams in acute myocardial infarction. Am. J. Cardiol. 1979- 44: 664−69.
103. Kaul S., Okada R. D., Pandian N. G., et al. Determination of left ventricular «area at risk» with high-resolution single photon emission computerized tomography in experimental coronary occlusion. Am. Heart J. 1985- 109: 1369−74.
104. Prigent F., Maddahi J., Garcia E. V., et al. Quantification of myocardial infarct size by thallium-201 single photon emission computerized tomography: Experimental validation in the dog. Circulation 1986- 74: 85 261.
105. Prigent F., Maddahi J., Garcia E. V., et al. Comparative methods for quantifying myocardial infarct size by thallium-201 SPECT. J. Nucl. Med. 1987- 28: 325−33.
106. Weiss R. J., Buda A. J., Pasyk S., et al. Noninvasive quantification of jeopardized myocardial mass in dogs using 2-dimensional echocardiography and thallium-201 tomography. Am. J. Cardiol. 1983- 52: 1340−44.
107. Keyes J. W., Brady T. J., Leonard P. F., et al. Calculation of viable and infarcted myocardial mass from thallium-201 tomograms. J. Nucl. Med. 1981- 22: 339−43.
108. Gerber K. H., Higgins C. B. Quantitation of size of myocardial infarctions by computerized transmission tomography. Invest. Radiol. 1983- 18: 238−44.
109. Granato J. E., Watson D. D., Flanagan T. L., et al. Myocardial thallium-201 kinetics during coronary occlusion and reperfusion: Influence of method of reflow and timing of thallium-201 administration. Circulation 1986- 73: 150 160.
110. Reduto L. A., Freund G. S., Garcia J. M. Coronary artery reperfusion in acute myocardial infarction: Benefical effects of intracoronary streptokinase on left ventricular salvage and perfomance. Am. Heart J. 1981- 102: 1162−77.
111. De Coster P. M., Melin J. A., Detry J. M., et al. Coronary artery reperfusion in acute myocardial infarction: Assessment by pre- and postintervention thallium-201 myocardial perfusion imaging. Am. J. Cardiol. 1985- 55: 88 995.
112. Schwarz F., Hofmann M., Schuler G., et al. Thrombolysis in acute myocardial infarction: Effect of intravenous followed by intracoronary streptokinase application on estimates of infarct size. Am. J. Cardiol. 1984- 53: 1505−10.
113. Schuler G., Schwarz F., Hofmann M., et al. Thrombolysis in acute myocardial infarction using intracoronary streptokinase: Assessment by thallium-201 scintigraphy. Circulation 1982- 66: 658−664.
114. Ritchie J. L., Davis K. B., Williams D. L., et al. Global and regional left ventricular function and tomographic radionuclide perfusion: The Western Washington Intracoronary Streptokinase in Myocardial Infarction Trial. Circulation 1984- 70: 867−75.
115. Deutsch E., Glavan K. A., Sodd V. J., et al. Cationic 99m Tc complexes as potential myocardial agents. J. Nucl. Med. 1981- V 22: 897−907.
116. Holman B. L., Jones A. G., Lister-James I, et al. A new Tc-99m-labeled myocardial imaging agent, Hexakis (t-Butylisonitril)-Technetium (1) (Tc-99m TBI): initial experience in the human. J. Nucl. Med. 1984- V 25: 13 501 355.
117. Jones A. G., Abrams M. I., Davison A., et al. Biological studies of new class of technetium complexes: the Hexakis (alkilisonitril) — technetium (1) cations. Int. J. Nucl. Med. Biol., 1989- V 11: 225−34.
118. Maddahi J., Roy L., Van Train K., et al. The first United States experiens in normal human myocardial imaging with Tc-99 metoxy isobutyl isonitrile (RP-30). Clin. Nucl. Med. 1986- V 11: 17 abst.
119. Berman D. S., Kiat H., Van Train K., et al. Technetium 99m sestamibi in the assessment of chronic coronary artery disease. Semin. Nucl. Med. 1991- V. 21: p. 190−212.
120. Sinusas A. J., Trautman K. A., Bergin J. D., et al. Quantification of area risk during coronary occlusion and degree of myocardial salvage after reperfusion with technetium-99m methoxyisobutyl isonitrile. Circulation 1990- V. 82: p. 1424−37.
121. Okada R. D., Glover D., Gaffney T., Williams S. Myocardial kinetics of technetium-99m-methoxy-2-methylpropyl-isonitrile. Circulation 1988- V. 77: p. 491−98.
122. Glover D., Okada R. D. Myocardial kinetics of Tc-MIBI in canine myocardium after dipyridamole. Circulation 1990- V. 81: p. 628−37.
123. Canby R. C., Silber S., Pohost G. M. Relations of the myocardial imaging agents 99mTc-MIBI and 201T1 to myocardial blood flow in a canine model of myocardial ischemic insult. Circulation 1990- V. 81: p. 289−96.
124. Beller G. A., Glover D. K., Ruiz M., et al. 99mTc-sestamibi uptake and retention during myocardial ischemia and reperfusion. Circulation 1993- V. 87: p. 2033−42.
125. Medrano R., Lowry R. W., Young U. B., et al. Assessment of myocardial viability with 99mTc sestamibi in patients undergoing cardiac transplantation. Circulation 1996- V. 94: p. 1010−1017.
126. Maes A. F., Borges M., Flameng W., et al. Assessment of myocardial viability in chronic coronary artery disease using 99mTc sestamibi SPECT. J. Am. Coll. Cardiol. 1997- V. 29: p. 62−68.
127. Christian T. F., Gibbons R. J., Gersh B. J. Effect of infarct location on myocardial salvage assessed by technetium-99m isonitrile. J. Am. Coll. Cardiol. 1991- 17: 1303−1308.
128. Hvid-Jacobsen K., Moller J. T., Kjller E., et al. Myocardial perfusion at fatal infarction: Location and size of scintigraphic defects. J. Nucl. Med. 1992- V. 33: p. 251−53.
129. Feiring A. J., Johnson M. R., Kioschos J. M., et al. The importance of th determination of the myocardial area at risk in the evaluation of the outcome c acute myocardial infarction in patients. Circulation 1987- V. 75: p. 980−87.
130. Christian T. F., Schwartz R. S., Gibbons R. J. Determinants of infarct size i reperfusion therapy for acute myocardial infarction. Circulation 1992- V. 86: j 81−90.
131. Gibbons R. J., Miller T. D., Christian T. F. Infarct size measured by single photon emission computed tomographic imaging with 99mTc-Sestamibi. Circulation 2000- 11: 101−108.
132. Gibbons R. J., Holmens D. R., Reeder G. S., et. al. Immidiate angioplasty compared with the administration of a thrombolytic agent followed by concervative treatment for myocardial infarction. N. Engl. J. Med. 1993- 328: 685−91.
133. Schaer G. L., Spaccarento L. J., Bronne K. F., et. al. Beneficial effects of RheothRX injection in patients receiving thrombolytic therapy for acute myocardial infarction. Circulation 1996- V.94: p. 298−307.
134. O’Keefe J. H., Grines C. L., DeWood M. A., et. al. Poloxamer-188 as an adjunct to primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am. J. Cardiol. 1996- V. 78: p. 747−50.
135. Collaborative Organization for RheothRX Evaluation (CORE). Effects of RheothRX on mortality, morbidity, left ventricular function, and infarct size in patients with acute myocardial infarction. Circulation 1997- V.96: p. 192 201.
136. Chareonthaitawee P., Christian T. F., Hirose K., et. al. Relation of infarct size t extent of left ventricular remodeling in the year after acute myocardial infarctioi J. Am. Coll. Cardiol. 1995- 25: 567−73.
137. Christian T. F., Behrenbek T., Gersh B. J., Gibbons R. J. Relation of left ventricular volume and function over one year after acute myocardial infarction to infarct size determined by technetium-99m sestamibi. J. Am. Cardiol. 1991- 68: 21−26.
138. Christian T. F., Clements I. P., Gibbons R. J. Noninvasive identification (myocardium at risk in patients with acute myocardial infarction and nondiagnosti electrocardiograms with technetium-99m sestamibi. Circulation 1991- V. 83:. 1615−20.
139. Wackers F. J., Gibbons R. J., Verani M. S., et al. Serial quantitative plam technetium-99m isonitrile imaging in acute myocardial infarction: Efficacy fcnoninvasive assessment of thrombolytic therapy. J. Am. Coll. Cardiol. 1989- 14: p. 861−873.
140. Gibson W. S., Behrenbeck Т., Pellikka P. A., et al. Serial tomographic imagin with technetium-99m-sestamibi for the assessment of infact-related arteri- patency following reperfusion therapy. J. Nucl. Med. 1992- V- 33: p. 2080−85.
141. Behrenbeck Т., Pellikka P. A., Gersh B. J. Primary angioplasty in myocardi- infarction: Assessment of improved myocardial perfusion with technetium-99i sestamibi. J. Am. Coll. Cardiol. 1991- V. 17: p. 365−72.
142. Clements I. P., Christian T. F., Higano S. Т., et al. Residual flow to the infari zone as a determinant of infarct size after direct angioplsty. Circulation 1993- 88: p. 1527−33.
143. Смирнов А. А. Косвенные признаки коронарной реперфузии у больных инфарктом миокарда. Бюллетень ВКНЦ АМН СССР 1988- 11:112−13.
144. Germano G., Erel J., Kiat H. et al. Quantitative LFEF and qualitative regional function from gated thallium-201 perfusion SPECT. J. Nucl. Med. 1997- 38: 379−54.
145. Wahba F. F. M., Bavelaar-Croon C. D. L., Baur L. H. B. et al. Detection of residual wall motion after sustained myocardial infarction by gated 99mTctetrofosmin SPECT: a comparison with echocardiography. Nucl. Med. Commun. 2001- 22: 175−82.
146. Wahba F. F. M., Lamb H. J., Bax J. J. et al. Assessment of regional myocardial wall motion and thickening by gated 99mTc-tetrofosmin SPECT: a comparison with magnetic resonance imaging. Nucl. Med. Commun. 2001- 22: 663−71.
147. Bax J. J., Lamb H. J., Dibbets P. et al. Comparison of gated single-photon emission computed tomography with magnetic resonance imaging for evaluation of left ventricular function in ischemic cardiomyopaty. Am. J. Cardiol. 2000- 15: 1299−1305.
148. Bavelaar-Croon C. D. L., Astma D. E., Van Der Wall E. E. et al. The additive value of gated SPET myocardial perfusion imaging in patients with known and suspected coronary artery disease. Nucl. Med. Commun. 2001- 22: 4555.
149. Kalbfleisch H., Hort W. Quantitative study on the size of coronary artery supplying areas postmorten. Am. Heart J. 1977- 94: 183−88.
150. Gibbons R. J., Holmens D. R., Reeder G. S., et. al. Immidiate angioplasty compared with the administration of a thrombolytic agent followed byconcervative treatment for myocardial infarction. N. Engl. J. Med. 1993- 328: 685−91.
151. Таланкина И. E. Морфологические особенности эволюции инфаркта миокарда после эффективной тромболитической терапии. Архив патологии 1998- 7: 63−70.
152. Rentrop К. R., Feit F., Sherman W., Thorton J. С. Serial angiographic assessment of coronary obstruction and collateral flow in acute myocardial infarction. Circulation 1989- 80: 1166−75.
153. Schwartz H., Leiboff R. H., Bren G. E. et al. Temporal evolution collateral circulation after myocardial infarction. J. Am. Coll. Cardiol. 1984- 4: 108 893.
154. Faraggi M., Montalescot G., Sarda L. et al. Spontaneous late improvement of myocardial viability in the chronic infarct zone is possible, depending on persistent TIMI 3 flow and a low grade stenosis of the infarct artery. Heart 1999−81:424−30.
155. Жукова H. С. Значение радионуклидных методов исследования в оценке эффективности тромболитической терапии у больных инфарктом миокарда. Диссертация кандидата мед. наук. Москва 1993.
156. Anderson J. L., Marshall H. W., Askins J. C., et. al. A randomized trial of intravenous and intracoronary streptokinase in patients with acute myocardial infarction Circulation 1984- 70: 606−18.
157. Kennedy J. W., Martin G., Devis K., et. al. The western Waschington intravenous streptokinase in acute myocardial infarction randomized trial. Circulation. 1988- 77: 345−50.
158. Guerci A. D., Gerstenblith G., Brinker J. A. et al. A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty. N. Engl. J. Med. 19Ь7- 317: 1613−1618.
159. Charuzi Y., Beeder C., Marshall L. A. et al. Improvement in regional and global ventricular function after intracoronary thrombolysis: assessment with two-dimensional echocardiography. Am. J. Cardiol. 1984- 53: 662−665.
160. Harrison J. K., Calif R. M., Woodlief L. H. et al. Systolic left ventricular function after reperfusion therapy for acute myocardial infarction. Circulation. 1993- 87: 1531−41.
161. Шальнев И. И. Влияние системной тромболитической терапии на сократительную функцию левого желудочка и толерантность к физической нагрузке у больных острым инфарктом миокарда. Тер. архив. 1996- 5: 55−56.
162. Староверов И. И. Тромболитическая терапия при остром инфаркте миокарда ОИМ. Диссертация доктора мед. наук. Москва. 1993.
163. Belenkie I., Knudston M. L., RothD. L. et al. Relation between flow grade after trombolytic therapy and the effect of angioplasty on left ventricular function: a prospective randomized trial. Am. Heart J. 1991- 121: 407−16.
164. Bourdillion D. V., Broderick T. M., Williams E. S. et al. Early recovery of regional left ventricular function after reperfusion in acute myocardial infarction assessed by serial two-dimensional echocardiography. Am. J. Cardiol. 1989- 63: 641−646.
165. Picard M. H., Wilkins G. T., Ray P., Weyman A. E. Long-term effects of acute thrombolytic therapy on ventricular size and function. Am. Heart J. 1993- 1: 1−10.
166. Pirolo J. S., Hutchins G. M., Moore G. W. Infarct expansion: pathologic analysis of 204 patients with a single myocardial infarct. J. Am. Coll. Cardiol. 1986- 7: 349−354.
167. Warren S. E., Royal H. D., Markis J. E. et al. Time course of left ventricular dilatation after myocardial infarction: influence of infarct-related artery and success of coronary thrombolysis. J. Am. Coll. Cardiol. 1988- 11: 12−19.
168. McKay R. G., Pfeffer M. A., Pasternak R. C. et al. Left ventricular remodeling after myocardial infarction: a corollary to infarct expansion. Circulation 1986- 74: 693−702.
169. Warren S. E., Royal H. D., Markis J. E. et al. Time course of left ventricular dilation after myocardial infarction: influence of infarct-related artery and success of coronary thrombolysis. J. Am. Coll. Cardiol. 1988- 11: 12−9.
170. Jeremy R. W, Hackworthy R. A., Bautovich G. et al. Infarct artery perfusion and changes in left ventricular volume in month after acute myocardial infarction. J. Am. Coll. Cardiol. 1987- 9: 989−995.
171. Hochman J. S.7 Choo H. Limitation of myocardial infarct expansion by reperfusion independent of myocardial salvage. Circulation 1987- 75: 299 306.
172. Glass B. A., Carter R. L., Albert H. M. Excision of myocardial infarcts. Arch. Surg. 1968- 97:940−46.
173. McCallister B. D., Christian T. F., Gersh B. J. et al. Prognosis of myocardial infarctions involving more than 40% of the left ventricle after acute reperfusion therapy. Circulation. 1993- 88: 1470−75.
174. In-hospital results and one-year follow-ap of GISSI trial (Gruppo Jtaliano per lo Studo: della Streptochinasi hell infarto miocardo) GISSI. J. Ital. Cardiol. 1987- 17: 20−29.
175. Чазов E. И., Руда M. Я., Николаева Л. Ф. Новые направления в лечении инфаркта миокарда. Тер. Архив 1987- 2: 5−12.
176. Арутюнов Г. П., Розанов А. В., Степанова Л. В. с соавт. Влияние тромболитической терапии на динамику недостаточностикровообращения и процессы ремоделирования миокарда левого желудочка. Кардиология. 2001- 3: 13−16.
177. Di Carli М., Davidson М., Little R. et al. Value of metabolic imaging with positron emission tomographic for evaluating prognostic in patients with coronary artery disease and left ventricular dysfunction. Am. J. Cardiol. 1994- 73: 527−33.
178. Bax J. J., Cornel J. H., Visser E. C. et al. Relation between extent of dysfunctional yet viable myocardium and improvement in LVEF after revascularization. (Abstr.) Eur. Heart J. 1997- 18: 574.